科研成果详情

名称SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study
作者
发表期刊Cancer communications (London, England)
语种英语
原始文献类型Letter
出版者WILEY
ISSN2523-3548
EISSN2523-3548
卷号44
期号8
页码910-914
DOI10.1002/cac2.12586
页数5
WOS类目Oncology
WOS研究方向Oncology
WOS记录号WOS:001264100600001
收录类别PUBMED ; SCIE ; SCOPUS
发布日期2024-07-08
URL查看原文
PubMed ID38976318
通讯作者地址[Li, Jin]Shanghai East Hosp, Dept Med Oncol, 1,800 Yuntai Rd, Shanghai 200123, Peoples R China.
Scopus学科分类Oncology;Cancer Research
SCOPUSEID2-s2.0-85197681328
引用统计
文献类型其他
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/215748
专题附属第一医院
第一临床医学院(信息与工程学院)、附属第一医院
附属第一医院_放化疗科
作者单位
1.Department of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China.;
2.Department of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China.;
3.Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China.;
4.Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China.;
5.Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, P. R. China.;
6.Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China.;
7.Department of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China.;
8.Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.;
9.Department of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China.;
10.Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.;
11.Department of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China.;
12.Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China.;
13.Department of Medical Oncology, Northern Jiangsu People's Hospital, Yangzhou, Jiangsu, P. R. China.;
14.Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China.;
15.Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China.;
16.Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China.;
17.Department of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China.;
18.Department of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China.;
19.Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.;
20.Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China.;
21.Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China.;
22.Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China.;
23.Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China.;
24.Department of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China.;
25.Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China.;
26.Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.;
27.Department of Oncology, The First People's Hospital of Changde City, Changde, Hunan, P. R. China.;
28.Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, P. R. China.;
29.Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China.;
30.Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.;
31.Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China.;
32.Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China.;
33.Department of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China.;
34.Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China.;
35.Department of Medical Oncology, Binzhou People's Hospital, Binzhou, Shandong, P. R. China.;
36.Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China.
推荐引用方式
GB/T 7714
Shuqui Qin,Jin Li,Aiping Zhou,et al. SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. 2024.

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Shuqui Qin]的文章
[Jin Li]的文章
[Aiping Zhou]的文章
百度学术
百度学术中相似的文章
[Shuqui Qin]的文章
[Jin Li]的文章
[Aiping Zhou]的文章
必应学术
必应学术中相似的文章
[Shuqui Qin]的文章
[Jin Li]的文章
[Aiping Zhou]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。